Skip to main content
. Author manuscript; available in PMC: 2022 Jan 11.
Published in final edited form as: Cancer Cell. 2020 Nov 19;39(1):38–53.e7. doi: 10.1016/j.ccell.2020.10.015

Figure 6. Exceptional Responders Often Exhibit Vulnerabilities in Multiple Categories.

Figure 6.

(A) Treatment timeline for ER0454 with metastatic endometrial carcinoma.

(B) Activating PIK3CA mutation and truncating PTEN mutation in ER0454.

(C) mRNA expression of MLH1 (left panel) and promoter methylation of MLH1 (right panel) in endometrial carcinomas (UCEC) in the ER and TCGA cohorts. Right panel, top are color-coded DNA methylation levels from 18 probes in the MLH1 promoter region (see heatmap color key to the right) for ER0454 and, negative control, ER0521. Right panel, bottom, are methylation data from probe cg00893636 versus MLH1 gene expression levels.

(D) Left panel, relative CD8 and CD3 mRNA expression levels in ER UCEC, all other ER, and TCGA cases. Purple asterisk is ER0454. Right panel, immunohistochemical analysis of CD3 and CD8 expression in tissue sections of ER0454. In both (C and D), box plots mark the 25th and 75th quartiles and the whiskers are 1.5 times the inter-quartile range; ER UCEC, n = 3; all other ER, n = 111; UCEC TCGA, n = 3.

UCEC, endometrial cancer.